Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 pr...
Gain Therapeutics reported positive Phase 1 results for GT-02287, showing safety and tolerability across all age groups. The co...
Oppenheimer analyst Jay Olson assumes Gain Therapeutics (NASDAQ:GANX) with a Outperform rating and announces Price Target of...
Chardan Capital analyst Keay Nakae maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $6 price target.
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 pr...
Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leadin...
